Here’s What Pushed Crispr Therapeutics AG Up 23.6% in December – Motley Fool
Dispatch Tribunal |
Here’s What Pushed Crispr Therapeutics AG Up 23.6% in December
Motley Fool Shares of Crispr Therapeutics AG (NASDAQ:CRSP), a biotech start-up named after the promising new gene-editing technology it’s focused on, bounded 23.6% higher in December, according to data from S&P Global Market Intelligence. A new collaboration deal … CRISPR Therapeutics Announces Proposed Public Offering of …GlobeNewswire (press release) A Comparison of Top Movers: Overstock.com, Inc. (OSTK), CRISPR Therapeutics AG (CRSP)StockNewsGazette Crispr Therapeutics (CRSP) Lifted to “Buy” at BidaskClubStockNewsTimes Dispatch Tribunal –Simply Wall St –The Ledger Gazette all 31 news articles » |
|
Atlas-backed Generation Bio promises ‘druglike’ gene therapy
FierceBiotech Backed by Atlas Ventures with a $25 million series A and headed by ex-Sobi CEO Geoff McDonough, Generation Bio says its lipid nanoparticle platform will allow it to offer the first genetic medicines that can be titrated to a particular dose—and … |
|
Cellect Bio’s ApoGraft stem cells completely accepted by first blood cancer patients in Phase 1/2 study; shares up …
Seeking Alpha Thinly traded nano cap Cellect Biotechnology (NASDAQ:APOP) is up 86% premarket on robust volume in response to encouraging results in a Phase 1/2 clinical trial assessing ApoGraft-processed donor-derived peripheral blood cells transplanted into blood … Cellect (APOP) Says First Group of Patients in Clinical Trial With its ApoGraft Stem Cell Transplant Follow up …StreetInsider.com Cellect Biotechnology | $APOP Stock | Shares Surge On Positive Stem Cell TrialWarrior Trading News (press release) UPDATE: Cellect Biotech shares rocket 65% premarket after unveiling stem cell breakthroughForexTV.com |